.svg){kind=small}
Apr-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In the competitive landscape of cannabis brands, Trilogy 710 has shown notable performance variations across different categories and states. In the state of California, Trilogy 710 made significant strides in the Concentrates category. Starting the year at the 30th position in January 2025, the brand improved its ranking to 12th in February before experiencing a slight dip to 16th in March, and then falling to 24th in April. This fluctuation indicates a dynamic market presence, with the brand achieving its peak ranking in February. The sales figures reflect this movement, with a notable increase from January to February, followed by a decline in the subsequent months.
While Trilogy 710's performance in California is notable, the absence of rankings in other states or categories suggests areas for potential growth or challenges in market penetration. The lack of top 30 rankings outside of California's Concentrates category could be seen as a limitation in their current market strategy or product appeal. This absence highlights the importance of diversifying their market presence and exploring opportunities in other states and product categories to enhance their overall brand performance. The insights from California's market dynamics could serve as a valuable benchmark for Trilogy 710 to strategize their expansion efforts in the coming months.
Competitive Landscape
In the competitive landscape of the California concentrates market, Trilogy 710 has experienced notable fluctuations in its rank from January to April 2025. Starting at rank 30 in January, Trilogy 710 made a significant leap to rank 12 in February, coinciding with a substantial increase in sales. However, by April, the brand's rank fell to 24, indicating a potential challenge in maintaining its earlier momentum. Competitors such as Nasha Extracts and Buddies have shown more consistent upward trends, with Buddies improving from rank 35 in January to 22 in April. Meanwhile, Everyday Cannabis Co. experienced a decline, dropping to rank 25 in April, which could provide Trilogy 710 an opportunity to reclaim market share if it can stabilize its performance. The data suggests that while Trilogy 710 has the potential for rapid growth, sustaining that growth amidst strong competition requires strategic adjustments.
Notable Products
In April 2025, Trilogy 710's top-performing products were 420 Special Live Rosin 1g and Country Lime Cold Cure Live Rosin 1g, both ranked first in the Concentrates category with notable sales figures of 152 units each. Peach Bellini Live Rosin 1g showed significant improvement, climbing to the second position from its previous fifth place in March, with sales of 135 units. Garlic Dawg Cold Cure Rosin 1g and Grape Gas Live Rosin 1g both secured the third rank, maintaining consistent sales figures of 113 units each. This marks a stable performance for Garlic Dawg and Grape Gas, which have consistently ranked third in the past months. Overall, Trilogy 710's products have demonstrated strong sales, with Peach Bellini showing the most notable upward movement in rankings.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
